Breast Cancer
Conditions
Keywords
Fulvestrant, Progression, Endocrine sensitivity
Brief summary
What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China.
Detailed description
There is no evidence of treatment after progression of Ful. We retrospectively evaluated HR+, HER2- MBC patients failed on Ful 500mg as first line or second line therapy from 2014 to 2017 in 6 institutions. Treatment pattern, PFS, OS and safety were analyzed to figure out the situation and efficacy of treatment after Fulvestrant.
Interventions
None listed
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients who were treated with Fulvestrant between June 2014 to June 2017 as first line or second line therapy * Patients received subsequent treatment after progressing on Fulvestrant for at least one cycle (\>1 month) * Complete medical history was available
Exclusion criteria
* Subsequent treatment was not standard therapy (cannot be classified into endocrine therapy/ chemotherapy) * Medical history was incomplete
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 6 weeks | Progression free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Overall survival |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | 6 weeks | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| Fulvestrant sensitivity | 6 weeks | Time cutoff of Fulvestrant PFS related to next line ET or CT efficacy |
Countries
China
Outcome results
None listed